Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

First Surgical Implant of ZIP ULTRA(TM) MIS Interspinous Device Performed in Israel

October 31, 2014 – 6:01 am | Edit Post

CARLSBAD, CALIFORNIA–(Marketwired – Oct. 31, 2014) – Aurora Spine Corporation (TSX VENTURE:ASG) announced today the first surgical implant of the company’s ZIP ULTRAT Minimally Invasive interspinous device in Israel. Multiple surgeries have now been performed at the Herzliya Medical Center by Prof. Reuven Gepstein.

First Surgical Implant of ZIP ULTRA(TM) MIS Interspinous Device Performed in Israel

October 31, 2014 – 6:01 am | Edit Post

CARLSBAD, CALIFORNIA–(Marketwired – Oct. 31, 2014) – Aurora Spine Corporation (TSX VENTURE:ASG) announced today the first surgical implant of the company’s ZIP ULTRAT Minimally Invasive interspinous device in Israel. Multiple surgeries have now been performed at the Herzliya Medical Center by Prof. Reuven Gepstein.

First Surgical Implant of ZIP ULTRA(TM) MIS Interspinous Device Performed in Israel

October 31, 2014 – 6:01 am | Edit Post

CARLSBAD, CALIFORNIA–(Marketwired – Oct. 31, 2014) – Aurora Spine Corporation (TSX VENTURE:ASG) announced today the first surgical implant of the company’s ZIP ULTRAT Minimally Invasive interspinous device in Israel. Multiple surgeries have now been performed at the Herzliya Medical Center by Prof. Reuven Gepstein.

First Surgical Implant of ZIP ULTRA(TM) MIS Interspinous Device Performed in Israel

October 31, 2014 – 6:01 am | Edit Post

CARLSBAD, CALIFORNIA–(Marketwired – Oct. 31, 2014) – Aurora Spine Corporation (TSX VENTURE:ASG) announced today the first surgical implant of the company’s ZIP ULTRAT Minimally Invasive interspinous device in Israel. Multiple surgeries have now been performed at the Herzliya Medical Center by Prof. Reuven Gepstein.

First Surgical Implant of ZIP ULTRA(TM) MIS Interspinous Device Performed in Israel

October 31, 2014 – 6:01 am | Edit Post

CARLSBAD, CALIFORNIA–(Marketwired – Oct. 31, 2014) – Aurora Spine Corporation (TSX VENTURE:ASG) announced today the first surgical implant of the company’s ZIP ULTRAT Minimally Invasive interspinous device in Israel. Multiple surgeries have now been performed at the Herzliya Medical Center by Prof. Reuven Gepstein.

Webcast Alert: Isis Pharmaceuticals, Inc.’ Third Quarter 2014 Financial Results Conference Call

October 31, 2014 – 5:00 am | Edit Post

CARLSBAD, Calif., Oct. 31, 2014 /PRNewswire/ –Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:

Vital Therapies, Inc. (VTI) Announces Third Quarter 2014 Financial Results Conference Call With Webcast And Upcoming Conference Presentation

October 31, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 30, 2014 (GLOBE NEWSWIRE) — Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD, a cell-based therapy targeting treatment of acute liver failure, will release its third quarter 2014 financial results after the market closes on Thursday, November 13, 2014. The…

Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures

October 31, 2014 – 5:00 am | Edit Post

SAN FRANCISCO, Oct. 31, 2014 /PRNewswire/ — Imago BioSciences, Inc., a biotech company developing innovative therapeutics, today announced a $26.5 million Series A financing led by Clarus Ventures LLC, a global investment firm founded by a team of accomplished investment and operating professionals dedicated to life sciences.  Other investors participating in the round include Frazier Healthcare, Amgen Ventures, and Merck Research Labs Venture Fund.  Representatives from Clarus Ventures and Frazier Healthcare will join the company’s board of directors.

“Imago BioSciences is extremely gratified with the makeup of this investment syndicate,” said Hugh Young Rienhoff, M.D., CEO at Imago BioSciences.  “They comprise a group of experienced financial and strategic investors who provide financial support to progress our clinical development program in a direction important to patients and their physicians.”

Proceeds from the financing will be used to advance the research and clinical development program of therapeutics that alter gene expression patterns.  The company’s clinical focus is on orphan diseases that involve genetic alterations disturbing normal patterns of gene expression, or diseases in which modifying gene expression patterns can have a therapeutic effect.

About Imago BioSciences

Imago BioSciences is a San Francisco-based clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians.  The company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases.  Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives.  More information is available at www.imagobio.com.
SOURCE Imago BioSciences

Mast Therapeutics Reports Third Quarter 2014 Financial Results

October 31, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 31, 2014 /PRNewswire/ — Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, today reported financial results for the quarter ended September 30, 2014. Brian M. Culley, the Company’s Chief Executive…

Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures

October 31, 2014 – 5:00 am | Edit Post

SAN FRANCISCO, Oct. 31, 2014 /PRNewswire/ — Imago BioSciences, Inc., a biotech company developing innovative therapeutics, today announced a $26.5 million Series A financing led by Clarus Ventures LLC, a global investment firm founded by a team of accomplished investment and operating professionals dedicated to life sciences.  Other investors participating in the round include Frazier Healthcare, Amgen Ventures, and Merck Research Labs Venture Fund.  Representatives from Clarus Ventures and Frazier Healthcare will join the company’s board of directors.

“Imago BioSciences is extremely gratified with the makeup of this investment syndicate,” said Hugh Young Rienhoff, M.D., CEO at Imago BioSciences.  “They comprise a group of experienced financial and strategic investors who provide financial support to progress our clinical development program in a direction important to patients and their physicians.”

Proceeds from the financing will be used to advance the research and clinical development program of therapeutics that alter gene expression patterns.  The company’s clinical focus is on orphan diseases that involve genetic alterations disturbing normal patterns of gene expression, or diseases in which modifying gene expression patterns can have a therapeutic effect.

About Imago BioSciences

Imago BioSciences is a San Francisco-based clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians.  The company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases.  Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives.  More information is available at www.imagobio.com.
SOURCE Imago BioSciences